Figure 3

PTV95 coverage (displayed as a percentage of prescribed dose) for pre-ICT versus post-ICT plans. 5 patients had initial pre-ICT plans that did not meet target coverage goals, of whom 2 derived benefit from chemotherapy (patients 1 and 6). 2 plans (patients 2 and 7) showed >5% compromised coverage for tumor volumes present following ICT.